

Infliximab Intravenous (Remicade®, Inflectra®, Renflexis®, Avsola™, Infliximab)

When requesting an infliximab intravenous product (Remicade, Inflectra, Renflexis, Avsola, Infliximab), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or approved off-label compendial uses and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indications

Infliximab intravenous is indicated for the treatment of:

- Crohn's disease
- Ulcerative colitis
- Rheumatoid arthritis
- Psoriatic arthritis
- Plaque psoriasis
- Ankylosing spondylitis

Approved Off-label Compendial Uses

- Behcet's disease
- Graft-versus-host disease
- Hidradenitis suppurativa
- Colitis, indeterminate
- Juvenile idiopathic arthritis
- Pyoderma gangrenosum
- Sarcoidosis
- Scleritis or sterile corneal ulceration
- Spondyloarthritis, other subtypes
- Uveitis
- Immunotherapy-related toxicities associated with checkpoint inhibitor therapy

Coverage Guidelines

Rheumatoid Arthritis (RA)

The individual must meet all of the following criteria for initial authorization:

- Is 18 years of age or older;
- Had a 3-month trial of at least one biologic agent or at least one conventional synthetic disease-modifying antirheumatic drug (DMARD);
- Infliximab intravenous is prescribed by or in consultation with a rheumatologist.

The individual must meet both of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., Clinical Disease Activity Index [CDAI], Patient Activity Scale [PAS]-II, Rapid Assessment of Patient Index Data 3 [RAPID-3], etc.); OR
 - Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints).

Ankylosing Spondylitis (AS)

The individual must meet both of the following criteria for initial authorization:

- Is 18 years of age or older;
- Infliximab intravenous is prescribed by or in consultation with a rheumatologist.

The individual must meet both of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., Ankylosing Spondylitis Disease Activity Score [ASDAS], Ankylosing Spondylitis Quality of Life Scale [ASQoL], Bath Ankylosing Spondylitis Disease Activity Index [BASDAI], serum markers [e.g., C-reactive protein, erythrocyte sedimentation rate], etc.); OR
 - Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain or stiffness; improvement in function or activities of daily living).

Psoriatic Arthritis (PsA)

The individual must meet both of the following criteria for initial authorization:

- Is 18 years of age or older;
- Infliximab intravenous is prescribed by or in consultation with a rheumatologist or a dermatologist.

The individual must meet both of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:

- Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., Disease Activity Index for Psoriatic Arthritis [DAPSA], Composite Psoriatic Disease Activity Index [CPDAI], Psoriatic Arthritis Disease Activity Score [PsA DAS], Psoriatic Arthritis Impact of Disease [PsAID-12], and/or serum markers); OR
- Has experienced an improvement in at least one symptom compared to baseline (e.g., less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints).

Crohn's Disease (CD)

The individual must meet all of the following criteria for initial authorization:

- Is 6 years of age or older;
- Infliximab intravenous is prescribed by or in consultation with a gastroenterologist.

The individual must meet both of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - Has experienced a beneficial clinical response in at least one objective measure compared to baseline (e.g., fecal markers, serum markers, imaging studies, endoscopic assessment, and/or reduced dose of corticosteroids); OR
 - Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain, fatigue, stool frequency, and/or blood in stool).

Ulcerative Colitis (UC)

The individual must meet both of the following criteria for initial authorization:

- Is 6 years of age or older;
- Infliximab intravenous is prescribed by or in consultation with a gastroenterologist.

The individual must meet both of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - Has experienced a beneficial clinical response in at least one objective measure compared to baseline (e.g., fecal markers, serum markers, imaging studies, endoscopic assessment, and/or reduced dose of corticosteroids); OR
 - Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain, fatigue, stool frequency, and/or rectal bleeding).

Plaque Psoriasis (PP)

The individual must meet all of the following criteria for initial authorization:

- Is 18 years of age or older;
- Meets one of the following:
 - Had a 3-month trial of or intolerance to at least one biologic agent, Otezla/Otezla XR (apremilast tablets/extended-release tablets), or Sotyktu (deucravacitinib tablets); OR
 - Had a 3-month trial of or intolerance to at least one traditional systemic agent (e.g., methotrexate, cyclosporine, acitretin, psoralen plus ultraviolet A light [PUVA]); OR
 - Has a contraindication to methotrexate therapy;
- Infliximab intravenous is prescribed by or in consultation with a dermatologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 3 months (*Note: A patient who has received < 3 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Has experienced a beneficial clinical response from baseline in at least one of the following: estimated body surface area affected, erythema, induration/thickness, and/or scale of areas affected by psoriasis;
- Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain, itching and/or burning).

Behcet's Disease

The individual must meet all of the following criteria for initial authorization:

- Is 6 years of age or older;
- Meets one of the following:
 - Has ophthalmic manifestations of Behcet's disease; OR
 - Had a trial of at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumab, etanercept); OR
 - Has tried at least one conventional therapy (e.g., systemic corticosteroids, immunosuppressant [e.g., azathioprine, methotrexate, mycophenolate mofetil]);
- Infliximab intravenous is prescribed by or in consultation with one of the following specialists: rheumatologist, dermatologist, ophthalmologist, gastroenterologist, or neurologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 3 months (*Note: A patient who has received < 3 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., best-corrected visual acuity if ophthalmic manifestations, serum markers, ulcer depth, number and/or lesion size);

- Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain, improved visual acuity if ophthalmic manifestations).

Graft-versus-Host Disease (GVHD)

The individual must meet all of the following criteria for initial authorization:

- Is 6 years of age or older;
- Has acute graft-versus-host disease;
- Has tried at least one systemic treatment for GVHD (e.g., cyclosporine, tacrolimus, mycophenolate mofetil, corticosteroids, an etanercept product, Jakafi, Nipent, a tocilizumab product, Entyvio);
- Infliximab intravenous is prescribed by or in consultation with an oncologist, hematologist, or a physician affiliated with a transplant center.

The individual must meet both of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 1 month (*Note: A patient who has received < 1 month of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., normalization of liver function tests, red blood cell count, or platelet count; resolution of fever or rash); OR
 - Has experienced an improvement in at least one symptom compared to baseline (e.g., improvement in skin, oral mucosal, ocular or gastrointestinal symptoms).

Hidradenitis Suppurativa

The individual must meet all of the following criteria for initial authorization:

- Is 18 years of age or older;
- Has tried one other therapy (e.g., intralesional or oral corticosteroids, systemic antibiotics, isotretinoin);
- Infliximab intravenous is prescribed by or in consultation with a dermatologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 3 months (*Note: A patient who has received < 3 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., Hurley staging, Sartorius score, Physician Global Assessment, Hidradenitis Suppurativa Severity Index);
- Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain or drainage of lesions, nodules, or cysts).

Colitis, Indeterminate

The individual must meet all of the following criteria for initial authorization:

- Is 6 years of age or older;
- Has tried one systemic corticosteroids;
- Has tried mesalamine;
- Has tried either azathioprine or 6-mercaptopurine;
- Infliximab intravenous is prescribed by or in consultation with a gastroenterologist.

The individual must meet both of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - Has experienced a beneficial clinical response in at least one objective measure compared to baseline (e.g., fecal markers, serum markers, imaging studies, endoscopic assessment, and/or reduced dose of corticosteroids); OR
 - Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain, fatigue, stool frequency, and/or rectal bleeding).

Juvenile Idiopathic Arthritis

The individual must meet all of the following criteria for initial authorization:

- Is 6 years of age or older;
- Meets one of the following:
 - Has tried one other systemic agent for this condition (e.g., adalimumab, etanercept, methotrexate, non-steroidal anti-inflammatory drug [NSAID]); OR
 - Has aggressive disease;
- Infliximab intravenous is prescribed by or in consultation with a rheumatologist.

The individual must meet both of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., Physician Global Assessment [MD global], Juvenile Arthritis Disease Activity Score [JDAS], Clinical Juvenile Arthritis Disease Activity Score [cJDAS], Juvenile Spondyloarthritis Disease Activity Index [JSpADA], reduced dosage of corticosteroids, etc.); OR
 - Has experienced an improvement in at least one symptom compared to baseline (e.g., improvement in limitation of motion, less joint pain/tenderness, decreased fatigue, improved function or activities of daily living).

Pyoderma Gangrenosum

The individual must meet all of the following criteria for initial authorization:

- Is 18 years of age or older;
- Meets one of the following:
 - Has tried one systemic corticosteroid (e.g., prednisone, methylprednisolone);
 - OR
 - Had a 2-month trial of or intolerance to at least one immunosuppressive agent (e.g., mycophenolate, cyclosporine);
- Infliximab intravenous is prescribed by or in consultation with a dermatologist

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 4 months (*Note: A patient who has received < 4 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Has experienced a beneficial clinical response from baseline in at least one of the following: size, depth, and/or number of lesions;
- Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain and/or tenderness of affected lesions).

Sarcoidosis

The individual must meet all of the following criteria for initial authorization:

- Is 18 years of age or older;
- Has tried at least one systemic corticosteroid;
- Has tried at least one immunosuppressive agent (e.g., methotrexate, azathioprine, leflunomide);
- Infliximab intravenous is prescribed by or in consultation with one of the following specialists: pulmonologist, ophthalmologist, cardiologist, neurologist, or dermatologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 3 months (*Note: A patient who has received < 3 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., lung function, serum markers, improvement in rash or skin manifestations, imaging studies, etc.);
- Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased cough, fatigue, pain, palpitations, and/or shortness of breath).

Scleritis or Sterile Corneal Ulceration

The individual must meet all of the following criteria for initial authorization:

- Is 18 years of age or older;
- Has tried one other therapy for this condition (e.g., non-steroidal anti-inflammatory drugs [NSAIDs], methotrexate, cyclosporine, corticosteroids);
- Infliximab intravenous is prescribed by or in consultation with an ophthalmologist.

The individual must meet both of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., serum markers [e.g., C-reactive protein, erythrocyte sedimentation rate]); OR
 - Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased eye pain, redness, light sensitivity, tearing, and/or improvement in visual acuity).

Spondyloarthritis (SpA), other subtypes

The individual must meet all of the following criteria for initial authorization:

- Is 18 years of age or older;
- Meets one of the following:
 - Has arthritis primarily in the knees, ankles, elbows, wrists, hands, and/or feet AND has tried at least one DMARD (e.g., methotrexate, leflunomide, sulfasalazine); OR
 - Has axial spondyloarthritis with objective signs of inflammation, defined as at least one of the following: C-reactive protein elevated beyond the upper limit of normal for the reporting laboratory or sacroiliitis reported on magnetic resonance imaging;
- Infliximab intravenous is prescribed by or in consultation with a rheumatologist.

The individual must meet both of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., Ankylosing Spondylitis Disease Activity Score (ASDAS), serum markers [e.g., C-reactive protein, erythrocyte sedimentation rate]); OR
 - Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain or stiffness, improvement in function or activities of daily living).

Uveitis

The individual must meet all of the following criteria for initial authorization:

- Is 6 years of age or older;
- Meets one of the following:
 - Has tried one of the following therapies: periocular, intraocular, or systemic corticosteroids, or immunosuppressive agent; OR
 - Had a trial of either an etanercept product (e.g., Enbrel) or an adalimumab product (e.g., Humira);
- Infliximab intravenous is prescribed by or in consultation with an ophthalmologist.

The individual must meet both of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., best-corrected visual acuity, assessment of chorioretinal and/or inflammatory retinal vascular lesions, etc.); OR
 - Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased eye pain, redness, light sensitivity, blurred vision, and/or improvement in visual acuity).

Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy

The individual must meet all of the following criteria for initial authorization:

- Is 18 years of age older;
- Developed an immunotherapy-related toxicity other than hepatitis (e.g., gastrointestinal system toxicity, inflammatory arthritis, ocular toxicity);
- Developed the immunotherapy-related toxicity while receiving a checkpoint inhibitor (e.g., Keytruda, Opdivo, Yervoy, Tecentriq, Bavencio, Imfinzi);
- Has tried one systemic corticosteroid (e.g., methylprednisolone, prednisone);
- Infliximab intravenous is prescribed by or in consultation with one of the following specialists: an oncologist, cardiologist, gastroenterologist, hematologist, nephrologist, pulmonologist, rheumatologist, or ophthalmologist.

The individual must meet both of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., improvement or normalization of serum markers [e.g., C-reactive protein, erythrocyte sedimentation rate], fecal markers, and/or reduced dosage of corticosteroids); OR

- Has experienced an improvement in at least one symptom compared to baseline (e.g., less joint pain/tenderness, stiffness or swelling, stool frequency; improved function of activities of daily living).

Approval duration (initial):

- GVHD: 1 month
- Plaque psoriasis/Behcet's disease/Hidradenitis suppurativa/Sarcoidosis: 3 months
- Pyoderma gangrenosum: 4 months
- All others: 6 months

Approval duration (renewal):

- GVHD: 3 months
- All others: 12 months

Dosing Recommendations

Infliximab is administered by intravenous infusion for at least 2 hours.

Crohn's disease, ulcerative colitis, indeterminate colitis, plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and pyoderma gangrenosum

The recommended dose is 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.

Graft-versus-host disease

The recommended dose is up to 10 mg/kg once weekly.

Rheumatoid arthritis

The recommended dose is 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.

Ankylosing spondylitis, Behcet's disease, sarcoidosis, and spondyloarthritis

The recommended dose is 5 mg/kg at 0, 2 and 6 weeks, then every 6 weeks.

Uveitis and immunotherapy-related toxicities associated with checkpoint inhibitor therapy

The recommended dose is up to 10 mg/kg at 0, 2 and 6 weeks, then every 4 weeks.

Juvenile idiopathic arthritis

The recommended dose is up to 6 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.

Scleritis or sterile corneal ulceration

The recommended dose is up to 10 mg/kg at 0, 2, 6, and 8 weeks.

References

1. Infliximab intravenous infusion [prescribing information]. Horsham, PA: Janssen; October 2021.
2. Inflectra® intravenous infusion [prescribing information]. Yeonsu-gu, Incheon, Republic of Korea: Celltrion/Pfizer; September 2025
3. Renflexis® intravenous infusion [prescribing information]. Jersey City, NJ: Samsung Bioepis/Organon; October 2025.
4. Avsola injection [prescribing information]. Thousand Oaks, CA: Amgen Inc.; August 2025.

5. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol*. 2019;(10):1599-1613.
6. Lichtenstein G, Loftus E, Afzali A, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. 2025 June;120(6):1225-1264.
7. Scott FI, Ananthakrishnan AN, Click B, et al. AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease. *Gastroenterology*. 2025 Dec;169(7):1397-1448.
8. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80(4):1029-1072.
9. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. *Arthritis Care Res (Hoboken)*. 2019;71(1):2-29.
10. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*. 2021;73(7):1108-1123.
11. Singh S, Loftus EV Jr, Limketkai BN, et al. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. *Gastroenterology*. 2024 Dec;167(7):1307-1343.
12. Rubin D, Ananthakrishnan A, Siegel C. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. *Am J of Gastroenterol*. 2025 June;120(6):1187-1224.
13. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. *Ann Rheum Dis*. 2018;77(6):808-818.
14. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology*. 2014;121(3):785-796.
15. The NCCN Hematopoietic Cell Transplantation (HCT) Clinical Practice Guidelines in Oncology (version 3.2025 – September 24, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on December 10, 2025.
16. Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management. *J Am Acad Dermatol*. 2019;81(1):91-101.
17. The NCCN Management of Immunotherapy-Related Toxicities Clinical Practice Guidelines in Oncology (version 1.2026 – October 23, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed December 10, 2025.
18. Papadakis KA, Treyzon L, Abreu MT, et al. Infliximab in the treatment of medically refractory indeterminate colitis. *Aliment Pharmacol Ther*. 2003;18:741-747.
19. Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. *Aliment Pharmacol Ther*. 2003;18:175-181.
20. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. *Arthritis Rheumatol*. 2022 Apr;74(4):553-569.
21. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. *Arthritis Rheumatol*. 2019;71(6):846-863.
22. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Rheum*. 2013;65(10):2499-2512.
23. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. *Eur Respir J*. 2021;58(6):2004079.
24. Riera E, Olivé A, Narváez J, et al. Adult onset Still's disease: review of 41 cases. *Clin Exp Rheumatol*. 2011;29(2):331-336.
25. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology – National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. *J Am Acad Dermatol*. 2020;82(6):1445-1486.
26. Nast A, Spuls PI, Dressler C, et al. EuroGuiDerm guideline for the systemic treatment of psoriasis vulgaris. Updated February 2025. Available at: <https://www.guidelines.edf.one/guidelines/psoriasis-guideline>. Accessed on: October 20, 2025.